Literature DB >> 1754104

Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis.

G Gaskin1, C O Savage, J J Ryan, S Jones, A J Rees, C M Lockwood, C D Pusey.   

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified as a diagnostic marker in primary systemic vasculitis, and immunofluorescence assays identify two patterns of binding: cytoplasmic (C-ANCA and perinuclear (P-ANCA). We have examined retrospectively the use of such assays in long-term monitoring of disease activity, in order to determine the relationship between presence of ANCA and relapse, and to assess their suitability as a guide to therapy. Seventy patients were studied over a period of 50 months, using clinical and laboratory criteria for the diagnosis of relapse and the internationally standardised immunofluorescence assay for detection of ANCA. In 19 patients C- or P-ANCA were detectable throughout the study period; six of these (with C-ANCA) relapsed. In 18 patients ANCA were undetectable during long-term follow-up; none of these patients relapsed. In 33 patients C- or P-ANCA were intermittently present; nine of these relapsed and all had C-ANCA detectable at the time of relapse. In six of the nine cases, relapse was accompanied or closely preceded by reappearance of C-ANCA. We conclude that continuing presence and reappearance of ANCA may identify patients who are at risk of relapse and who are most likely to benefit from long-term immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1754104     DOI: 10.1093/ndt/6.10.689

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  27 in total

Review 1.  Pathogenesis and treatment of ANCA-associated systemic vasculitis.

Authors:  A D Salama
Journal:  J R Soc Med       Date:  1999-09       Impact factor: 5.344

Review 2.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Role of proteinase 3 in activation of endothelium.

Authors:  M E Taekema-Roelvink; C van Kooten; C A Verburgh; M R Daha
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

Review 5.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 6.  New horizons in renal vasculitis.

Authors:  J S Cameron
Journal:  Klin Wochenschr       Date:  1991-09-03

Review 7.  Pulmonary vasculitis.

Authors:  A Burns
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 8.  Assessment of disease activity in systemic vasculitis.

Authors:  W Y Tse; P Cockwell; C O Savage
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

9.  AP-VAS 2012 case report: MPO-ANCA-negative relapse of MPO-ANCA-associated vasculitis.

Authors:  Yoshinori Komagata; Kazufumi Nomura; Ken Yoshihara; Soko Kawashima; Shinya Kaname; Yoshihiro Arimura; Akira Yamada
Journal:  CEN Case Rep       Date:  2013-11-07

Review 10.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.